Nicotine Studies Shown to Have Therapeutic Properties

In the vaping industry, there’s always going to be articles we come across that is completely bogus or in this case, supported by actual researchers who know what they’re doing (cause you know, they do research for a living). How many times have you come across a post about “Vape battery caught on fire, teen sent to hospital” or “Popcorn lungs found in e-liquid products” and just think about how fast the media tries to portray vapor products as a dangerous and unhealthy habit. Now, we’re not saying that vaping is 100% safe but, there are currently not enough studies validating whether or not vaping can kill you because the industry is fairly new. So far there have been no known deaths linked to the inhalation of vapor products. We can only say that for several thousands of users, e-cigarettes have aided in their process of dropping those cancer sticks and saving their lives.

As you may already know, e-liquids contain nicotine (of course there are no nicotine options available) and does not contain tobacco. Two very different components. Cigarettes however contain both, making vapor products an alternative to remove the combustion of tobacco altogether while still getting that nicotine “fix”. Nicotine being a highly addictive substance has actually been proven to have therapeutic properties and a negative association with diseases like Alzheimer’s and Parkinson’s.

“The nicotinic acetylcholine receptors themselves come in several varieties. One, designated the alpha-7 nicotinic acetylcholine receptor (or alpha-7 nAChR), abounds on nerve cells in many distinct regions of the brain; defects in its function have been fingered in both Alzheimer’s disease and schizophrenia.

It happens that the alpha-7 nicotinic receptor is also found on certain types of immune cells that can act as suppressors and regulators of the immune system. And, it turns out, a new study in Proceedings of the National Academy of Sciences, conducted by Steinman, Rothbard and their peers shows, that those very amyloid-forming proteins can activate this very receptor, on these very immune cells, resulting in a dialing down of inflammation.

Bottom line: alpha-7 nAChR-activating drugs might have therapeutic benefits in a variety of inflammatory diseases. Steinman and Rothbard are working to develop small-molecule therapeutics targeting this receptor and safe for human use against rheumatoid arthritis, gout, inflammatory bowel disease and multiple sclerosis.”

Read the full article from Stanford Medicine here.

Leave a Reply

Your email address will not be published. Required fields are marked *